CN Patent

CN109456373A — 核苷氨基磷酸酯前药

Assigned to Gilead Sciences Inc · Expires 2019-03-12 · 7y expired

What this patent protects

本文公开了用于治疗哺乳动物病毒性感染的(S)‑2‑{[(2R,3R,4R,5R)‑5‑(2,4‑二氧代‑3,4‑二氢‑2H‑嘧啶‑1‑基)‑4‑氟‑3‑羟基‑4‑甲基‑四氢呋喃‑2‑基甲氧基]‑苯氧基‑磷酰基氨基}‑丙酸异丙酯或其立体异构体，以及包含其的组合物及其制备方法。

USPTO Abstract

本文公开了用于治疗哺乳动物病毒性感染的(S)‑2‑{[(2R,3R,4R,5R)‑5‑(2,4‑二氧代‑3,4‑二氢‑2H‑嘧啶‑1‑基)‑4‑氟‑3‑羟基‑4‑甲基‑四氢呋喃‑2‑基甲氧基]‑苯氧基‑磷酰基氨基}‑丙酸异丙酯或其立体异构体，以及包含其的组合物及其制备方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN109456373A
Jurisdiction: CN
Classification: —
Expires: 2019-03-12
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.